120results about How to "Toxic and side effects" patented technology

The invention relates to a polymer composition loaded with a sirolimus compound or its derivative. The composition can have diversified forms. A necessary link includes preparing the sirolimus compound or its derivative and a polymer carrier into a micelle. Then according to needs, the micelle can be further prepared into a freeze-dried composition by a freeze-drying technology, or the micelle and other polymer and carrier can be prepared into a solid or semi-solid preparation. The polymer composition can be used for treating tumors, reducing rejection reactions after organ and tissue transplantation, promoting cell regeneration and repair, preventing excessive scar tissue growth after injury and preventing vascular restenosis and blood coagulation embolism, treating or inhibiting autoimmune diseases, and treating or inhibiting inflammation, etc.

The invention provides application of a sesquiterpene compound 6-OAP in preparation of STAT3 inhibitors and in treatment of diseases unusually relevant to STAT3, and a pharmaceutical composition for treatment of diseases unusually relevant to STAT3. The pharmaceutical composition contains 6-OAP. 6-OAP can quickly combine with STAT3, can significantly inhibit phosphorylation of STAT3 in a cell and animal tumor-bearing model and significantly inhibit the activity of STAT3 induced by inflammatory factors, and has no significant toxic and side effect on other normal tissues. With the advantages of proper dose, significant curative effect, definite action target, and low toxic and side effects, etc., the 6-OAP has wide anticancer and anti-inflammatory application prospects clinically.

The invention discloses a traditional Chinese medicine composition for treating climacteric syndrome. The traditional Chinese medicine composition is prepared from the following crude drugs: radix bupleuri, radix paeoniae alba, radix curcumae, dogwood, common yam rhizome, mulberry fruit, spina date seed, light wheat, tuber fleeceflower stem, keel, oyster, lotus nut, lily, prepared rehmannia root, rhizoma anemarrhenae, astragalus membranaceus, radix ophiopogonis, schisandra chinensis, fruit of Chinese wolfberry, seed of Chinese dodder, tuckahoe, bighead atractylodes rhizome, root bark of the peony tree, corbicula, soybean sprout, tortoise shell, laportea, bayuezha (Chinese character), filbert, and nacre mother of pearl. The traditional Chinese medicine composition can treat the climacteric syndrome, and can soothe the liver and regulate qi, nourish yin and invigorate the spleen, and nourish yin and yang. The technology has the advantages of being convenient to dose, through in affected part, strong in targeting property, low in cost and the like; and a drug is easily prepared. The traditional Chinese medicine composition adopts different drug properties of traditional Chinese medicinal materials; scientific formulation is carried out; and an ideal treatment effect can be achieved. The traditional Chinese medicine composition is safe, and free of toxic and side effects, can replenish the vital essence and remove heat in combination of oral administration and external application, and can eliminate dampness and dredge channels, and remove pain.

The invention relates to a chemically synthesized staphylococcus aureus surface protein FnBPA gene fragment, as well as expression and application thereof, belonging to the fields of genetic engineering technologies, antibodies and kits. According to the chemically synthesized staphylococcus aureus surface protein FnBPA gene fragment provided by the invention, a strong antigen epitope, namely 133 amino acids in total from 745th amino acid to 877th amino acid in the staphylococcus aureus surface protein FnBPA are screened out through computer analysis, a codon preferred by prokaryotes is selected, a brand new gene sequence of the antigen epitope is chemically synthesized, the gene fragment is expressed by utilizing the genetic engineering technology, and the strong antigen epitope fragment of the staphylococcus aureus surface protein FnBPA is prepared. The expressed strong antigen epitope fragment of the staphylococcus aureus surface protein FnBPA can be used for detection of staphylococcus aureus antibodies and immune preparation of anti-staphylococcus aureus monoclonal antibodies, polyclonal antibodies and the like.

The invention discloses a monoclonal antibody and a preparation method thereof. The monoclonal antibody comprises anti-PGAM, CoI alpha, Trx, PGAM 13, CoI alpha 12 and Trx 11. The preparation method comprises the following steps: immunizing mice by embedding PGAM, CoI alpha, Trx, PGAM 13, CoI alpha 2 and Trx 11 in spleens; fusing spleen cells of the mice with myeloma cells SP2/0 of the mice; and detecting the cells by indirect ELISA and culturing supernatant. 3, 2, 5, 3, 4 and 3 strains of monoclonal antibodies for resisting PGAM, CoI alpha, Trx, PGAM 13, CoI alpha 12 and Trx 11 are respectively obtained, and homotypes of the antibodies are IgM.

The invention discloses an antisense oligodeoxynucleotide for a micro RNA-155 seed sequence and an application. Micro antisense nucleic acids t-antimiR-155 of eight basic groups are designed and synthesized for the miR-155 seed sequence. T-antimiR-155 transfection cell test shows that t-antimiR-155 is targeted to miRNA-155 of a RPMI-8266 cell strain, so that cell growth is remarkably inhibited and apoptosis is remarkably increased. The test shows that t-antimiR-155 can effectively inhibit growth of lymphoma cells by interfering expression of the miRNA-155, and meanwhile, the test shows that the miRNA-155 can probably be taken as a potential target spot for gene therapy of lymphoma. The t-antimiR-155 can be used for preparing anti-tumor medicines, and particularly medicines for treating multiple myeloma.

The invention discloses a purification technique of biodegradable polyesters. The purification technique comprises: (1) mixing an organic solvent with the polyesters to prepare a solution containing the polyesters and having a concentration of the polyesters between 0.05 to 8 g / 100 ml; (2) mixing an extractant with the solution and performing extraction, separating an organic phase which contains the polyesters, and concentrating the organic phase to obtain a concentrate; and (3) mixing the concentrate with a precipitant and stirring, and drying after liquid-solid separation. The organic solvent used in step (1) is acetonitrile, N,N-dimethylformamide or N,N-dimethylacetamide; the extractant used in step (2) is an alkane, the number of carbon atoms in which is between 5 and 8; and the volume ratio of the organic solvent to the extractant in step (1) is between 1:2 and 1:10. The technique can effectively remove catalysts, oligomers, monomers and the organic solvent in the biodegradable polyesters, so that high quality biodegradable polymer particles can be obtained.

The invention discloses a pellet type pantoprazole sodium enteric capsule and a preparation method thereof. The pellet type pantoprazole sodium enteric capsule is a sustained-release preparation composed of a capsule shell and uniformly mixed pantoprazole sodium pellets held in the capsule shell; the pantoprazole sodium pellet from inside to outside in turn comprises a blank pellet core, a main drug layer, an isolation layer and an enteric layer, wherein the weight of the main drug layer is 14-55% of that of the blank pellet core, the weight of the isolation layer is 9-10% of that of the total weight of the blank pellet core and the main drug layer, the weight of the enteric layer is 28-32% of that of the total weight of the blank pellet core, the main drug layer and the isolation layer; 40-60% of that of the pantoprazole sodium pellet is coated with a pigmented layer on the outside of the enteric layer; the weight of the pigmented layer is 0.5-1% of that of the total weight of the blank pellet core, the main drug layer, the isolation layer and the enteric layer; the diameter of the blank pellet core is 0.8-1.0 mm; the granularity of the pantoprazole sodium pellet is 14-20 mesh; each capsule contains 20-40 mg of the pantoprazole sodium. The pellet type pantoprazole sodium enteric capsule has the advantages of acidproof, rapid release and stable.

The invention discloses a preparation method and application of a tilapia source streptococcus agalactiae recombinant GroEL protein vaccine. The recombinant GroEL protein vaccine is prepared by tilapia source streptococcus agalactiae recombinant GroEL protein. An amino acid sequence of the tilapia source streptococcus agalactiae recombinant GroEL protein is as shown in SEQ ID NO.2. In the invention, tilapia source streptococcus agalactiae is taken as a research object, a GroEL gene is obtained from a tilapia source streptococcus agalactiae genome by cloning, the cloned GroEL gene is connected with a pET28a(+) carrier to construct an expression vector, and the vector is subjected to prokaryotic expression and purification in E.coli BL21(DE3) to obtain the recombinant GroEL protein vaccine with strong specificity and an immune protective efficacy of 68.61+/-7.39 percent, so that a foundation is laid for immune prevention and treatment of a tilapia streptococcus agalactiae disease.

The invention discloses mesoporous silica-lactobionic acid targeted nanoparticles loaded with Sorafenib/siRNA and an application of the mesoporous silica-lactobionic acid targeted nanoparticles loaded with the Sorafenib/siRNA in preparing of anticancer therapy drugs. The targeted nanoparticles are prepared through the steps that surface amination modifying is conducted on mesoporous silica nanoparticles; then inner pore channels of the mesoporous silica nanoparticles are internally loaded with the Sorafenib; and lactobionic acid is covalently coupled to the outer surfaces of the mesoporous silica nanoparticles, and the siRNA is adsorbed on the outer surfaces of the mesoporous silica nanoparticles through the electrostatic adsorption effect. According to the drug loading system, the stability of the siRNA can be improved, and targeted drug delivery of the Sorafenib can be further achieved, so that the toxic and side effects of the mesoporous silica-lactobionic acid targeted nanoparticles on normal cells are effectively relieved.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a strychnine gel preparation and a preparation method thereof. The gel preparation comprises 0.5%-1% of strychnine, 0.5%-3% of a gel skeleton, 10%-30% of a cosolvent and the balance of water. According to the prepared strychnine hydrogel, simple pharmaceutic adjuvants are used, no transdermal enhancer isused, but the transdermal effect is excellent, and the strychnine hydrogel is easy to spread, good in biocompatibility, good in skin absorption, good in drug membrane adhesiveness and free of irritation to skin and mucous membranes.

The invention discloses a mini-pill type nicergoline capsule and a preparation method thereof. The mini-pill type nicergoline capsule is a sustained-release preparation and is prepared from a capsule shell and a nicergoline mini-pill accommodated in the capsule shell, wherein the nicergoline mini-pill sequentially comprises an empty pill core, a main drug layer and a pigmented layer from inside to outside; the main drug layer accounts for 15-60 percent of the empty pill core, and the pigmented layer accounts for 0.5-1 percent of the total weight of the empty pill core and the main drug layer. The mini-pill type nicergoline capsule has the advantages of small stimulation to intestines and stomach, high utilization rate, high stability, less toxic or side effects and capability of fully releasing effective components in time.

The invention relates to a production method of a bone spur pain-eliminating capsule, which comprises the steps of treating dahurian angelica root, Chinese angelica and semen coicis, treating radix aconiti preparata, radix aconiti agrestis praeparata and gentiana macrophylla, treating paniculate swallowwort root and other steps. By adopting the method, the yield of paeonol in the paniculate swallowwort root is greatly increased, the water consumption during extraction is greatly reduced, the distillation time is greatly shortened and the energy consumed for extraction is remarkably reduced and the utilization rate of the equipment is remarkably improved. Therefore, the invention has unexpected technical effects, remarkable economic benefits and wide application prospect.

The invention provides applications of a circRRM2B gene as a new target in screening Vemurafenib-resistant melanoma treatment drugs. The drugs take the circRRM2B gene as a target and inhibit or silence the expression of the circRRM2B gene. Applications of reagents for inhibiting or silencing the expression of the circRRM2B gene in preparing drugs for inhibiting melanoma are also provided. Throughchip screening, the circRRM2B is found being related to the Vemurafenib resistance of the melanoma and is the new target to screen the Vemurafenib-resistant melanoma treatment drugs, so that the circRRM2B gene has positive significance on screening new drugs. Meanwhile, the discovery of the new target provides a new thought for the treatment of drug-resistant melanoma.

The invention discloses a pellet type omeprazole enteric capsule and a preparation method thereof. The pellet type omeprazole enteric capsule is a sustained-release preparation, and is composed of a capsule shell and evenly mixed omeprazole pellets received in the capsule shell; each omeprazole pellet is composed of a blank pill core, a main drug layer, an isolation layer and an enteric layer in order from inside to outside, wherein the weight of the main drug layer accounts for 15-60% of that of the blank pill core, the weight of the isolation layer accounts for 10% of the total weight of the blank pill core and the main drug layer, the weight of the enteric layer accounts for 28-32% of the total weight of the blank pill core, the main drug layer and the isolation layer; besides, the enteric layers of 40-60% of omeprazole pellets are further coated with pigment layers; the weight of the pigment layer accounts for 0.5-1% of the total weight of the blank pill core, the main drug layer, the isolation layer and the enteric layer; the diameters of the blank pill cores are 0.8-1.0mm; the granularity of the omeprazole pellets is 14-20 meshes; each capsule contains 15-30mg of omeprazole. The pellet type omeprazole enteric capsule has the advantages of good acid resistance, sufficient active ingredient release without delay, good stability and the like.

The invention belongs to the field of biological medicines, and relates to an application of baicalin in preparation of a medicine for preventing and/or treating asymptomatic hyperuricemia and/or uricacid nephropathy. Based on animal and cell experiments, the effect of baicalin on hyperuricemia nephropathy is studied, and the result shows that baicalin can inhibit the activity of xanthine oxidase, inhibit uric acid generation, reduce the serum uric acid level of mice with uric acid nephropathy and remarkably improve the renal function of the mice. The baicalin inhibits damage of sodium uratecrystals to rat renal tubular epithelial cells by reducing secretion of TNF alpha, IL-1beta, lactate dehydrogenase and NO.

A cataplasm for treating lumbar interveterbral disc protrusion belongs to the technical field of traditional herbal medicinal preparations with undetermined structures. The cataplasm for treating lumbar interveterbral disc protrusion has the advantages of use convenience, good curative effect, fast effectiveness, no need of administration of Chinese or western medicines, no toxic side effects, and avoiding of pains of physicotherapy or operations. The cataplasm comprises the following traditional Chinese medicinal components: 10-15g of Radix Aconiti, 8-12g of Rhizoma Arisaematis, 2-6g of Rhizoma Drynariae, 8-12g of rosin, 8-12g of Rhizoma Pinelliae Preparatum, 6-10g of Chinese angelica, 8-12g of Crocus sativus, 12-18g of Radix Clematidis, 3-8g of Manchurian wildginger, 8-12g of Incised Notopterygium, 1-5g of borneol, 8-12g of camphor, 12-18g of Rheum officinale, 8-12g of peach seed, 3-8g of Semen Brassicae, 6-10g of Chinese Taxillus Twig, 10-15g of Eucommia ulmoides, 12-18g of Achyranthes bidentata, 3-8g of centipede, and also comprises the following matrix materials: 5-10% of methyl salicylate, 1-5% of sodium benzoate, 25-30% of glycerin, 1-5% of polysorbate, 10-15% of gelatin, 1-5% of carbomer, 1-5% of camphor, 1-5% of kaolin, 5-10% of sodium polyacrylate, and the balance of water.

The invention relates to a 5-azacytidine compound and a preparation method thereof. The structural formula of the 5-azacytidine compound is shown in a formula I (shown in the specification). The compound is obtained from 5-azacytosine as a starting material by upper protection, condensation, deprotection, recondensation and a deprotection rection. Through studies of related substances, recognitionand control of an impurity profile in the 5-azacytidine compound are strengthened, the quality of a finished product is advantageously controlled, and a guarantee is provided for the safety of clinical medication. The synthesis process is simple in operation, good in yield and purity, and is environment friendly.

The invention belongs to the technical field of medicine, in particular to the use of coumaric acid in preparing a medicine for treating human acute lymphoblastic leukemia, which has the advantages oflow toxicity, small side effect, high selectivity, low price and the like.